Co-distribution of sensory gating and impaired niacin flush response in the parents of schizophrenics

Schizophrenia Research

Volumn 40, Issue 1, 1999, Pages 49-53

  Waldo, Merilyne C ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Fatty acid metabolism; Genetics; Niacin flush response; Schizophrenia; Sensory gating

Indexed keywords

NICOTINIC ACID;

ADULT; ARTICLE; AUDITORY NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; FATTY ACID METABOLISM; FEMALE; FLUSHING; HEREDITY; HUMAN; MALE; PHENOTYPE; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSORY NERVE; VASODILATATION;

EVOKED POTENTIALS, AUDITORY; FLUSHING; HUMANS; NIACIN; PARENTS; PERCEPTUAL DISORDERS; SCHIZOPHRENIA;

EID: 0032887135     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(99)00031-6     Document Type: Article

References (34)

1. Baker N.J., Staunton M., Adler L.E., Gerhardt G.A., Drebing C., Waldo M.C., Nagamoto H., Freedman R. Sensory gating deficits in psychiatric inpatients: relation to catecholamine metabolites in different diagnostic groups. Biol. Psychiatry. 27:1990;519-528.
2. Basketter D.A., Wilhelm K.P. Studies on non-immune immediate contact reactions in an unselected population. Contact Dermatitis. 35:(4):1996;237-240.
3. Bates C., Horrobin D.F., Ells K. Fatty acids in plasma phospholipids and cholesterol esters from identical twins concordant and discordant for schizophrenia. Schizophr. Res. 6:(1):1991;1-7.
4. Dykes P., Marks R. An evaluation of the irritancy potential of iodine solutions: comparison of subjective and objective assessment techniques. Clin. Exp. Dermatol. 17:1992;246-249.
5. Essex T.J.H., Byrne P.O. A laser Doppler scanner for imaging blood flow in skin. J. Biomed. Eng. 13:1991;189-194.
6. Freedman R., Coon H., Myles-Worsley M., Orr-Urtreger A., Olincy A., Davis A., Polymeropoulos M., Holik J., Hopkins J., Hoff M., Rosenthal J., Waldo M.C., Reimherr F., Wender P., Yaw J., Young D.A., Breese C.R., Adams C., Patterson D., Adler L.E., Kruglyak L., Leonard S., Byerley W. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc. Natl. Acad. Sci. USA. 94:(2):1997;587-592.
7. Gattaz W.F., Hubner C.K., Nevalainen T.J., Thuren T., Kinninen P.K.J. Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biol. Psychiatry. 28:1990;495-501.
8. Glen A.I., Cooper S.J., Rybakowski J., Vaddadi K., Brayshaw N., Horrobin D.F. Membrane fatty acids, niacin flushing and clinical parameters. Prostaglandins Leukotrienes Essent. Fatty Acids. 1-2:1996;9-15.
9. Hitzemann R., Hirschowitz J., Panini A., Mark C., Garver D. Membranes, methylation and lithium responsive psychoses. Nutr. Health. 3:(3):1984;153-162.
10. Horrobin D.F. A possible relationship between dyslexia and schizophrenia, two disorders in which membrane phospholipid metabolism is disturbed. Schizophr. Res. 18:1996;156.
11. Kaiya H., Horrobin D.F., Manku M.S., Fisher N.M. Essential and other fatty acids in plasma in schizophrenics and normal individuals from Japan. Biol. Psychiatry. 30:(4):1991;357-362.
12. Laugharne J.D., Mellor J.E., Peet M. Fatty acids and schizophrenia. Lipids. (Suppl.):1996;S163-S165.
13. Mahadik S.P., Mukherjee S., Horrobin D.F., Jenkins K., Correnti E.E., Scheffer R.E. Plasma membrane phospholipid fatty acid composition of cultured skin fibroblasts from schizophrenic patients: comparison with bipolar patients and normal subjects. Psychiatry Res. 63:(2-3):1996;133-142.
14. Mathe A.A., Eberhard F., Saaf J., Wetterberg L. Plasma prostglandin E2 metabolite-measured as 11-deoxy-15-13, 14-dihydro-11 beta, 16 xi-cyclo-PGE2 - in twins with schizophrenic disorder. Biol. Psychiatry. 21:(11):1986;1024-1030.
15. Mattsson U., Krogstad A.-L., Pegenius G., Elam M., Jontell M. Assessment of erythema and skin perfusion by digital image analysis and scanner laser Doppler. Skin Res. Technol. 3:1997;53-59.
16. Nagamoto H.T., Adler L.E., Waldo M.C., Freedman R. Sensory gating in schizophrenics and normal controls: effects of changing stimulation interval. Biol. Psychiatry. 25:1991;549-561.
17. Nelson M.D., Saykin A.J., Flashman L.A., Riordan H.J. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging. Arch. Gen. Psychiatry. 55:1998;433-440.
18. Noponen M., Sanfilipo M., Samanich K., Ryer H., Ko F., Angrist B., Wokin A., Duncan E., Rostrosen J. Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol. Psychiatry. 34:(9):1993;641-649.
19. Peet M., Laugharne J., Rangarajan N., Horrobin D.F., Reynolds G. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J. Psychiatr. Res. 29:(3):1995;227-232.
20. Peet, M., Ramchand, C.N., Shah, S., Unmedicated Patients Fail to Flush in Response to Topical Niacin. XXI CINP Congress, Glasgow, July 1998.
21. Pettegrew J.W., Keshavan M.S., Panchalingam K., Strychor S., Kaplan D.B., Tretta M.G., Allen M. Alterations in brain-energy phosphate and membrane phospholipid metabolism in first episode, drug-naïve schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 48:(6):1991;563-568.
22. Risch N. Linkage strategies for genetically complex traits. I. Multilocus models. Am. J. Hum. Genet. 46:(2):1990;222-228.
23. Ross B.M., Hudson C., Erlich J., Warsh J.J., Kish S.J. Increases phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2. Arch. Gen. Psychiatry. 54:1997;487-494.
24. Rybakowski J., Weterle R. Niacin test in schizophrenia and affective illness. Biol. Psychiatry. 29:(8):1991;834-836.
25. Siegel C., Waldo M., Mizner G., Adler L.E., Freedman R. Deficits in sensory gating in schizophrenic patients and their relatives. Evidence obtained with auditory evoked responses. Arch. Gen. Psychiatry. 41:(6):1984;607-612.
26. Strohman R. Epigenesis: the missing beat in biotechnology? Biotechnology. 12:(2):1994;156-164.
27. Vaddadi K.S., Gilleard C.J., Soosai E., Polonowita A.K., Gibson R.A., Burrows G.D. Schizophrenia, tardive dyskinesia and essential fatty acids. Schizophr. Res. 20:(3):1996;287-294.
28. van Kammen D.P., Yao J.K., Goetz K. Polyunsaturated fatty acids, prostaglandins, and schizophrenia. Ann. NY Acad. Sci. 559:1989;411-423.
29. Waldo M.C., Carey G., Myles-Worsley M., Cawthra E., Adler L.E., Nagamoto H.T., Wender P., Byerley W., Plaetke R., Freedman R. Co-distribution of sensory gating deficit and schizophrenia in multi-affected families. Psychiatry Res. 39:1991;257-268.
30. Waldo M.C., Cawthra E., Adler L.E., Dubester S., Staunton M., Nagamoto H., Baker N., Madison A., Simon J., Scherzinger A., Drebing C., Gerhardt G., Freedman R. Auditory sensory gating, hippocampal volume and catecholamine metabolism in schizophrenics and their siblings. Schizophr. Res. 12:1994;93-106.
31. Waldo M.C., Myles-Worsley M., Madison A., Byerley W., Freedman R. Sensory gating deficits in parents of schizophrenics. Am. J. Med. Genet. 60:(6):1995;506-511.
32. Ward P.E., Sutherland J., Glen E.M.T., Glen A.I.M. Niacin skin flush in schizophrenia: A preliminary report. Schizophr. Res. 29:1998;269-274.
33. Wilson D.W.S., Douglas A.B. Niacin skin flush is not diagnostic of schizophrenia. Biol. Psychiatry. 21:1986;974-977.
34. Yao J.K., Van Kammen D.P., Welker J.A. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr. Res. 13:(3):1994;217-226.